- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04968171
Diabetes Type 1 and Fitness. (Diab1Fit)
Assessment of Physical Effort in People With Newly Diagnosed Type 1 Diabetes Mellitus and Its Impact on: Partial Clinical Remission, Insulin Resistance, HDL Cholesterol Function, Immune Function and Length of Life.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
The Diab1Fit Study project aims to a multidirectional assessment of physical activity and its impact in people with type 1 diabetes (DM1). To the study are recruited people with newly diagnosed DM1, treated with intensive functional insulin therapy from the beginning of the disease. The study is planned to cover a minimum of 100 people with newly diagnosed DM1 and lead prospective observation of this group (for a minimum of 5-10 years). The investigators will evaluate the effect of VO2max in people with newly diagnosed DM1 on partial clinical remission. What is more the investigators also assess quantitative and qualitative changes of plasma lipoproteins, with particular emphasis on HDL metabolism, mechanism linking VO2max with management of DM1 (longevity proteins, miostatin, insulin resistance) and immune function.
Patients will be assessed: during the first hospitalization in the moment of diagnosis (prior to introduction of insulin treatment), after 3 weeks, after 6 months and after 12 months of insulin therapy. Further observations planned in the annual intervals. Further continuous observation with follow-up every year and evaluation of final end-points after 5 and 10 years. In addition, the study group will be under constant monitoring of metabolic evaluation every three months in the Outpatient Clinic. An additional visit to assess VO2max will be scheduled between 3 and 12 months of diabetes. The investigators will use an ergospirometer (COSMED K5 System) during an exercise test carried out on a cycloergometer (progressive exercise test). Moreover, the investigators will monitor glucose levels during the exercise test - using a continuous glucose monitoring system using the FreeStyle Libre Flash Glucose Monitoring System (Abbott). A week before the exercise test, the investigators will borrow a Garmin watch that assesses the patient's daily activities
During each follow-up will be assessed parameters:
- The presence of partial clinical remission, according to Mortensen: HbA1c (%) + [4 x dawka insuliny (j/kg/d)] ≤ 9.
- Data on lifestyle (diet, exercise), family history and smoking.
Anthropometric data:
- BMI (body mass index) = weight [kg]/(height [m])2
- Waist circumference
- WHR - waist to hip ratio
- daily insulin requirement (U/kg m.c./d),
- eGDR (estimated glucose disposal rate) = 24.31-12.22(WHR)-3.29(hypertension 0/1)-0.57( HbA1c [mg/kg/min])
VAI (visceral adiposity index):
For women = [Waist circumference/36.58+(1.89xBMI)]x(TG/0.81)x(1.52/HDL), For men = [Waist circumference /39.68+(1.88xBMI)]x(TG/1.03)x(1.31/HDL),
- body composition analysis
Parameters of diabetes metabolic control
- Lipid profile
- Glycated hemoglobin level (HbA1c)
- Protein glycation end products Expected impact of the research project on the development of science, civilization and society: The study confirms the great importance of aerobic physical activity in the treatment of people with DM1 from the beginning of the diagnosis. The project aims to pay attention to the importance of physical activity among people with DM1 and to popularize this method of treatment. The obtained results will be used for the prospective observation of this group to assess the impact of physical effort on the development of chronic complications and will allow planning intervention studies in this population. The results of this study will help enrich knowledge about the body's ability to exercise among people with DM1 and show new intervention solutions. It may contribute to changing the recommendations of scientific societies. What is more knowledge about prolonging partial clinical remission and thereby reducing the risk of developing chronic complications will contribute to the introduction of new recommendations. Research on exercise in diabetes and longevity proteins will increase the length and quality of life of people with DM1.
Studientyp
Einschreibung (Voraussichtlich)
Kontakte und Standorte
Studienorte
-
-
-
Poznan, Polen, 60-834
- Rekrutierung
- Department of Internal Medicine and Diabetiology Poznan University of Medical Sciences
-
Kontakt:
- Justyna Flotyńska
- Telefonnummer: +48 728328961
- E-Mail: justynaflotynska@gmail.com
-
Kontakt:
- Aleksandra Uruska, PhD
- Telefonnummer: +48 607620750
- E-Mail: aleksandrauruska@gmail.com
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Age 18-35 years,
- New onset type 1 diabetes (confirmed by the presence of antibodies - antyGAD, ICA, IA2)
- Treatment with intensive insulin therapy,
- Written consent to participate in the study.
Exclusion Criteria:
- Contraindications to the exercise test (including: recent myocardial infarction, unstable coronary artery disease, hypertrophic cardiomyopathy, serious arrhythmias, myocarditis, advanced systemic diseases, hyperthyroidism, recurrent anemia),
- Mental disorders,
- Co-morbidities with potential impact on physical performance (e.g. cancer, renal failure, liver failure, rheumatic diseases, COPD, asthma, anemia, hypothyroidism and hyperthyroidism),
- Pregnancy.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: Nur Fall
- Zeitperspektiven: Interessent
Kohorten und Interventionen
Gruppe / Kohorte |
---|
People with newly diagnosed diabetes mellitus type 1
People with newly diagnosed diabetes mellitus type 1 admitted to the Department of Internal Medicine and Diabetology. Treated with intensive insulin therapy. Measurement of VO2max between 3 and 12 month after diagnosis. Further continuous observation with follow-up every year and evaluation of final end-points after 5 and 10 years. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
VO2max [ml/min/kg]
Zeitfenster: 1 year
|
VO2 max level evaluated during ergospirometry (COSMED K5)
|
1 year
|
Partial clinical remission time
Zeitfenster: 1 year
|
Presence [(4 x insulin dose (j/kg/d)] ≤ 9] and duration [time] of partial clinical remission
|
1 year
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Triglicerydes concentriation in serum [mg/dl]
Zeitfenster: Change from baseline in apolipoproteins' at 6 and 12 months
|
Changes in serum triglyceride levels
|
Change from baseline in apolipoproteins' at 6 and 12 months
|
LDL-C concentriation in serum [mg/dl]
Zeitfenster: Change from baseline in apolipoproteins' at 6 and 12 months
|
Changes in serum LDL levels
|
Change from baseline in apolipoproteins' at 6 and 12 months
|
HDL-C concentriation in serum [mg/dl]
Zeitfenster: Change from baseline in apolipoproteins' at 6 and 12 months
|
Changes in serum HDL levels
|
Change from baseline in apolipoproteins' at 6 and 12 months
|
Total Cholesterol concentriation in serum [mg/dl]
Zeitfenster: Change from baseline in apolipoproteins' at 6 and 12 months
|
Changes in serum Total-CH levels
|
Change from baseline in apolipoproteins' at 6 and 12 months
|
Lipid tissue content [%]
Zeitfenster: 5 years
|
Evaluation of lipid tissue content prior to yearly visit.
|
5 years
|
A1c [%]
Zeitfenster: 5 years
|
Changes in serum A1c levels
|
5 years
|
Daily insulin requirement [u/kg/d]
Zeitfenster: 1 year
|
Sum of insulin units administered in the day prior to yearly visit.
|
1 year
|
Retinopathy
Zeitfenster: 5 years
|
Evaluation of retinopathy (ophthalmology assessment)
|
5 years
|
Neuropathy
Zeitfenster: 5 years
|
Evaluation of presence of neuropathy peripheral and autonomic (clinical examination, Visual Analog Score for pain and ProsciCard)
|
5 years
|
eGFR [ml/min/1,73m2]
Zeitfenster: 5 years
|
Assessment of glomerular filtration and renal filtration function
|
5 years
|
Creatynine [mg/dl]
Zeitfenster: 5 years
|
Assessment of renal function
|
5 years
|
Albumine to creatynine ratio ACR [mg/g]
Zeitfenster: 5 years
|
Assessment of renal function
|
5 years
|
Mitarbeiter und Ermittler
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 1050/19
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Diabetes Mellitus
-
Medical College of WisconsinMedical University of South CarolinaAbgeschlossenDiabetes Mellitus | Typ 2 Diabetes mellitus | Altersdiabetes mellitus | Nicht insulinabhängiger Diabetes mellitus | Nicht insulinabhängiger Diabetes Mellitus, Typ IIVereinigte Staaten
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.AbgeschlossenDiabetes mellitus, Typ 1 | Diabetes Typ 1 | Diabetes Typ1 | Diabetes mellitus Typ 1 | Autoimmundiabetes | Diabetes mellitus, insulinabhängig | Jugenddiabetes | Diabetes, Autoimmun | Insulinabhängiger Diabetes mellitus 1 | Diabetes mellitus, insulinabhängig, 1 | Diabetes mellitus, spröde | Diabetes mellitus... und andere BedingungenVereinigte Staaten
-
Guang NingRekrutierungTyp 2 Diabetes mellitus | Diabetes mellitus Typ1 | Monogenetischer Diabetes | Pankreatogener Diabetes | Medikamenteninduzierter Diabetes mellitus | Andere Formen von Diabetes mellitusChina
-
SanofiAbgeschlossenDiabetes mellitus Typ 1 – Diabetes mellitus Typ 2Ungarn, Russische Föderation, Deutschland, Polen, Japan, Vereinigte Staaten, Finnland
-
Meir Medical CenterAbgeschlossenDiabetes mellitus Typ 2 | Diabetes mellitus, nicht insulinabhängig | Diabetes mellitus, zur oralen hypoglykämischen Behandlung | Diabetes mellitus vom ErwachsenentypIsrael
-
Joslin Diabetes CenterCambridge Medical Technologies, LLCAbgeschlossenTyp 2 Diabetes mellitus | Diabetes mellitus Typ1Vereinigte Staaten
-
Hanmi Pharmaceutical Company LimitedUnbekanntTyp 2 Diabetes mellitus | Diabetes mellitus Typ1Vereinigte Staaten
-
Hoffmann-La RocheRoche DiagnosticsAbgeschlossenDiabetes mellitus Typ 2, Diabetes mellitus Typ 1Deutschland
-
University of California, San FranciscoJuvenile Diabetes Research FoundationAbgeschlossenDiabetes mellitus Typ 1 | Diabetes mellitus, Typ I | Insulinabhängiger Diabetes mellitus 1 | Diabetes mellitus, insulinabhängig, 1 | IDDMVereinigte Staaten, Australien
-
Leiden University Medical CenterAndaluz Health ServiceAbgeschlossenDiabetes Mellitus | Gesundheitsverhalten | Selbstwirksamkeit | Typ 2 Diabetes mellitus | Diabetes mellitus Typ1Niederlande, Spanien